Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

T Benson

Showing results (261-270 of 271) with videos related to

Pageof 28
Sort By:
Therapeutic Innovation & Regulatory Science|February 20, 2020
Shared Learnings on the New EMA First-in-Human and Early Clinical Trial Guideline: Proceedings From a DIAlogue Session at DIA Europe 2018Jan Willem van der Laan, Charles T Benson, Walter Janssens, et al.
Neurology. Clinical Practice|April 17, 2023
Measuring Ambulatory Racial and Ethnic Neurologic Disparities With the Axon RegistryRichard T Benson, Sarah M Benish, Gregory J Esper, et al.
Andrology|March 13, 2018
Development of a selective androgen receptor modulator for transdermal use in hypogonadal patientsV Krishnan, N J Patel, J G Mackrell, et al.
The Lancet. Diabetes & Endocrinology|October 31, 2015
Myostatin antibody (LY2495655) in older weak fallers: a proof-of-concept, randomised, phase 2 trialClemens Becker, Stephen R Lord, Stephanie A Studenski, et al.
Diabetic Medicine : a Journal of the British Diabetic Association|March 4, 2020
A standard set of person-centred outcomes for diabetes mellitus: results of an international and unified approachJ Nano, F Carinci, O Okunade, et al.
Clinical Pharmacology and Therapeutics|September 1, 2020
Time for a Fully Integrated Nonclinical-Clinical Risk Assessment to Streamline QT Prolongation Liability Determinations: A Pharma Industry PerspectiveHugo M Vargas, Michael G Rolf, Todd A Wisialowski, et al.
Physical Review Letters|July 31, 2025
Dark Matter Search Results from 4.2  Tonne-Years of Exposure of the LUX-ZEPLIN (LZ) ExperimentJ Aalbers, D S Akerib, A K Al Musalhi, et al.
Physical Review Letters|December 13, 2024
Constraints on Covariant Dark-Matter-Nucleon Effective Field Theory Interactions from the First Science Run of the LUX-ZEPLIN ExperimentJ Aalbers, D S Akerib, A K Al Musalhi, et al.
Physical Review Letters|July 31, 2025
New Constraints on Cosmic Ray-Boosted Dark Matter from the LUX-ZEPLIN ExperimentJ Aalbers, D S Akerib, A K Al Musalhi, et al.
Physical Review Letters|July 31, 2025
First Constraint on Atmospheric Millicharged Particles with the LUX-ZEPLIN ExperimentJ Aalbers, D S Akerib, A K Al Musalhi, et al.
Pageof 28

Showing results (261-270 of 271) with videos related to

Sort By:
Pageof 28
Therapeutic Innovation & Regulatory Science|February 20, 2020
Shared Learnings on the New EMA First-in-Human and Early Clinical Trial Guideline: Proceedings From a DIAlogue Session at DIA Europe 2018Jan Willem van der Laan, Charles T Benson, Walter Janssens, et al.
Neurology. Clinical Practice|April 17, 2023
Measuring Ambulatory Racial and Ethnic Neurologic Disparities With the Axon RegistryRichard T Benson, Sarah M Benish, Gregory J Esper, et al.
Andrology|March 13, 2018
Development of a selective androgen receptor modulator for transdermal use in hypogonadal patientsV Krishnan, N J Patel, J G Mackrell, et al.
The Lancet. Diabetes & Endocrinology|October 31, 2015
Myostatin antibody (LY2495655) in older weak fallers: a proof-of-concept, randomised, phase 2 trialClemens Becker, Stephen R Lord, Stephanie A Studenski, et al.
Diabetic Medicine : a Journal of the British Diabetic Association|March 4, 2020
A standard set of person-centred outcomes for diabetes mellitus: results of an international and unified approachJ Nano, F Carinci, O Okunade, et al.
Clinical Pharmacology and Therapeutics|September 1, 2020
Time for a Fully Integrated Nonclinical-Clinical Risk Assessment to Streamline QT Prolongation Liability Determinations: A Pharma Industry PerspectiveHugo M Vargas, Michael G Rolf, Todd A Wisialowski, et al.
Physical Review Letters|July 31, 2025
Dark Matter Search Results from 4.2  Tonne-Years of Exposure of the LUX-ZEPLIN (LZ) ExperimentJ Aalbers, D S Akerib, A K Al Musalhi, et al.
Physical Review Letters|December 13, 2024
Constraints on Covariant Dark-Matter-Nucleon Effective Field Theory Interactions from the First Science Run of the LUX-ZEPLIN ExperimentJ Aalbers, D S Akerib, A K Al Musalhi, et al.
Physical Review Letters|July 31, 2025
New Constraints on Cosmic Ray-Boosted Dark Matter from the LUX-ZEPLIN ExperimentJ Aalbers, D S Akerib, A K Al Musalhi, et al.
Physical Review Letters|July 31, 2025
First Constraint on Atmospheric Millicharged Particles with the LUX-ZEPLIN ExperimentJ Aalbers, D S Akerib, A K Al Musalhi, et al.
Pageof 28